HAITONG UT(01905)Guotai Junan Securities and Haitong will implement and complete the proposed merger.
Haitong Hengxin (01905) issued an announcement stating that the Board of Directors of the company is aware that Haitong Securities and Guotai Junan Securities will merge in January 2025.
HAITONG UT (01905) announced that the company's board of directors is aware that Haitong Securities and Guotai Junan Securities jointly issued a latest progress announcement on the proposed merger on January 20, 2025.
As stated in the latest progress announcement on the proposed merger, the effectiveness and implementation conditions of the merger agreement signed between Haitong and Guotai Junan Securities have been met, and Guotai Junan Securities and Haitong will implement and complete the proposed merger.
After the proposed merger is completed, Haitong will no longer be the ultimate controlling shareholder of the company. Guotai Junan Securities (as the surviving company) will become the indirect controlling shareholder of the company, and Shanghai International Group Co., Ltd. (as the actual controller of the surviving company) will become the actual controller of the company.
Related Articles
HK Stock Market Move | SICC Co., Ltd. (02631) rose more than 8%, and silicon carbide became the new route for chip cooling. The company is a leading enterprise in silicon carbide substrates.
HK Stock Market Move | AKESO(09926) rose nearly 3% in early trading. Recently, the CD47 Lafflet single antibody was granted FDA orphan drug status.
New stock first day | Kingway Pharmaceuticals-B (02595) debuted on the market with an opening increase of 115.79% in the morning session. Its core product GFH925 has already been commercialized domestically.
HK Stock Market Move | SICC Co., Ltd. (02631) rose more than 8%, and silicon carbide became the new route for chip cooling. The company is a leading enterprise in silicon carbide substrates.
HK Stock Market Move | AKESO(09926) rose nearly 3% in early trading. Recently, the CD47 Lafflet single antibody was granted FDA orphan drug status.
New stock first day | Kingway Pharmaceuticals-B (02595) debuted on the market with an opening increase of 115.79% in the morning session. Its core product GFH925 has already been commercialized domestically.
RECOMMEND
Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025
Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025
SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025
